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Liver Cancer–Specific Serine Protease Inhibitor Kazal
Is a Potentially Novel Biomarker for the Early Detection
of Hepatocellular Carcinoma
Felix Lu, BS1, Pir Ahmad Shah, MD2, Abhishek Rao, MS1, Cynthia Gifford-Hollingsworth, MD3, Anne Chen, MS1, Gary Trey, MD2,
Mina Soryal,MS1, Arslan Talat, MD2, Aysha Aslam,MD2, Bilal Nasir, MD2, Saad Choudhry,MD2, Rizwan Ishtiaq,MD2, Hanna Sanoff, MD4,
Lanla F. Conteh, MD5, Anne Noonan, MD5, Ke-Qin Hu, MD6, Carl Schmidt, MD7, Min Fu, PhD8, Jesse Civan, MD9, Gary Xiao, MD3,
Daryl T.-Y. Lau, MD2 and Xuanyong Lu, PhD1
INTRODUCTION: Liver cancer–secreted serine protease inhibitor Kazal (LC-SPIK) is a protein that is specifically elevated
in cases of hepatocellular carcinoma (HCC). We assessed the performance of LC-SPIK in detecting
HCC, including its early stages, in patients with cirrhosis, hepatitis B virus (HBV), and hepatitis C virus
(HCV).
METHODS: We enrolled 488 patients, including 164 HCC patients (81 early HCC) and 324 controls in a blinded,
prospective, case–control study. Serum LC-SPIK levels were determined by an enzyme-linked
immunosorbent assay-based assay. The performance of serum LC-SPIK and a-fetoprotein (AFP),
including area under the curve (AUC), sensitivity, and specificity, are compared. The performance of
LC-SPIK was evaluated in an independent validation cohort with 102 patients.
RESULTS: In distinguishing all HCCpatients from thosewith cirrhosis and chronicHBV/HCV, LC-SPIKhad anAUC
of 0.87, with 80% sensitivity and 90% specificity using a cutoff of 21.5 ng/mL. This is significantly
higher than AFP, which had an AUC of 0.70 and 52% sensitivity and 86% specificity using a standard
cutoff value of 20.0 ng/mL. For early-stage HCC (Barcelona Clinic Liver Cancer stage 0 andA), LC-SPIK
had an AUC of 0.85, with 72% sensitivity and 90% specificity, compared with AFP, which had an AUC
of 0.61, with 42% sensitivity and 86% specificity. In addition, LC-SPIK accurately detected the
presence of HCC in more than 70% of HCC patients with false-negative AFP results.
DISCUSSION: The study provided strong evidence that LC-SPIK detects HCC, including early-stage HCC, with high
sensitivity and specificity, and might be useful for surveillance in cirrhotic and chronic HBV/HCV
patients, who are at an elevated risk of developing HCC.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A434
Clinical and Translational Gastroenterology 2020;11:e00271. https://doi.org/10.14309/ctg.0000000000000271
INTRODUCTION
Primary hepatocellular carcinoma (HCC) is the most common
form of liver cancer, with an estimated 854,000 cases in 2015, and
is associated with high mortality (1–5). It is often undiagnosed
until its later stages where curative treatment options are more
limited than those in earlier stages, and 5-year survival rate drops
to less than 15%. By contrast, the survival rate is more than 50%
with detection of HCC at earlier stages (1,2,6,7). The poor
prognosis of HCC can be overcome with sensitive and accurate
diagnostic assays, which can detect the cancer in its earliest and
most treatable stages.
Existing tools for HCC surveillance include liver ultrasound
and a-fetoprotein (AFP). Ultrasound is the primary surveillance
tool, whereas AFP is only optionally recommended per American
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Association for the Study of Liver Diseases guidelines and the
European Association for the Study of the Liver makes no rec-
ommendation forAFPdue to its poor performance (4,8). Although
ultrasound is noninvasive, it is operator and equipment dependent
and not sensitive enough to detect HCC in its critical early stages,
with an estimated sensitivity below 50% (6,9). For tumor sizes less
than 2 cm, the sensitivity of ultrasound is only 21% (9,10). In
addition, ultrasound is suboptimal in certain subpopulations such
as obese patientswith highbodymass index and thosewith a coarse
liver echotexture (4,8,11). AFP, which is still the most commonly
tested biomarker for HCC, suffers frompoor performance, with an
estimated 41%–65% sensitivity and 80%–90% specificity, using a
cutoff value of 20.0 ng/mL (12,13). AFP is worse in detecting early-
stage HCC, with sensitivity rate less than 40% (12,14). In addition,
nearly 40% of patients with HCC have undetectable AFP levels in
their sera (13,15–17), andpatientswith chronic liver diseasesmight
have falsely elevated AFP levels during active inflammation (18).
These factors highlight the limited application of AFP in HCC
surveillance programs and weaknesses with ultrasound. Other
potential biomarkers, such as AFP-L3 and des-g-(4) prothrombin,
are only approved for risk stratification, not surveillance, and suffer
from low sensitivities in early-stage HCC (4). Biopsies or other
radiologicalmethods such asCT scans andMRIs are expensive and
burdensome screening modalities and not appropriate for regular
surveillance. An accurate and cost-effective solution for HCC
surveillance remains a significant unmet need.
To address this, we investigated the performance of a protein
called liver cancer–secreted serine protease inhibitor Kazal (LC-
SPIK). LC-SPIK is a liver cancer–specific isoform of serine pro-
tease inhibitor Kazal (SPIK), which also called pancreas secretory
trypsin inhibitor and tumor-associated trypsin inhibitor (19,20).
Normally, SPIK has no or limited activity in liver tissues or in any
tissues besides the pancreas. However, recent studies have
reported that the expression of SPIK is elevated in HCC (21–23).
The use of SPIK as a cancer biomarker before has been impeded
by the fact that serum SPIK levels are also elevated in other
conditions such as acute pancreatitis (24–26). We have demon-
strated that the SPIK protein secreted by liver cancer cells is
unique as it retains an additional N-terminal fragment during
secretion (27). We call this HCC-specific SPIK isoform “liver
cancer SPIK” or LC-SPIK. To determine whether this isoform is
cancer specific and differentiable fromnormal or pancreatic SPIK
(pan-SPIK), we developed a monoclonal antibody immobilized
with a monoclonal anti-LC-SPIK antibody (IM-MCA), which
solely recognizes LC-SPIK, and then an enzyme-linked
immunosorbent assay (ELISA)-based diagnostic kit. Using this
kit, we evaluated LC-SPIK performance in distinguishing HCC
from cirrhosis and chronic hepatitis B virus (HBV)/hepatitis C
virus (HCV) in a prospective, blinded clinical study and the po-
tential as a novel HCC biomarker.
MATERIALS AND METHODS
Determining serum levels of LC-SPIK and AFP
Serum levels of LC-SPIK were quantified using the ELISA test kit
we developed and validated, following a standardized protocol
described in the kit’s instructions for use. In brief, the 96-well
plate was IM-MCA; 10 mL of each specimen was diluted with
dilution buffer to 100mL and incubated with the plate at 37° C for
1 hour. To ensure accuracy of the test results, each sample was
tested in triplicate. A standard calibrator set consisting of six 100-
mL samples of HPLC-purified LC-SPIK at various concentrations
(100, 50, 20, 4, 1, and 0 ng/mL) and positive and negative controls
were incubated with the plate. After washing, 100mL of conjugate
(polyclonal anti-SPIK antibody labeled with horse peroxidase)
was added and incubated at 37° C for 45 minutes. The color was
developed after incubation with tetramethylbenzidine at room
temperature for 20 minutes, and the OD450 nmwas determined.
The mean and SD of the OD450-nm values for each sample was
calculated after the test, and the concentration of LC-SPIK levels
was determined using the standard curve generated with the
calibrator set. The analytical performance of the test kit is de-
scribed in the Supplementary Material (Supplementary Digital
Content 1, http://links.lww.com/CTG/A434). Serum levels of
AFP was determined by partner institutions in their clinical
laboratories using US Food and Drug Administration (FDA)-
approved AFP tests, including the Beckman Coulter UniCel DxI,
Siemens Immulite XPi, and Ortho Clinical Diagnostics AFP test.
Western blot
Patient sera and controls (purified LC-SPIK from stable cell line
S2-3 and pan-SPIK from PanC1 cells) (27) were separated by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS PAGE) and transferred to polyvinylidene difluoride
(PVDF)membrane. SPIK protein was visualized by staining with
a polyclonal anti-SPIK antibody and then with a standard anti-
mouse secondary antibody conjugated with horseradish peroxi-
dase. An ECL Advance Western Blotting Detection Kit (GE
Healthcare, Piscataway, NJ) was used to visualize the image.
Sample population
Serum samples for the primary study were collected prospectively
from a total of 488 unique study subjects enrolled in 6 separate
clinical sites. These institutions include Beth Israel Deaconess
Medical Center, Teaching Hospital of Harvard Medical School,
Drexel University College of Medicine, Thomas Jefferson Uni-
versity, Ohio State University, University of California, Irvine,
and University of North Carolina. Of those 488 patients, there
were 164 HCC patients including 81 patients with early-stage
HCC (Barcelona Clinic Liver Cancer [BCLC] stage 0-A). There
were 324 controls, including 245 with liver diseases (125 liver
cirrhosis and 120 chronic HBV/HCV) and 79 healthy patients.
For the independent validation study, additional 102 sera were
obtained from a well-characterized biorepository at Beth Israel
Deaconess Medical Center. Of these, 45 samples were collected
from HCC patients, including 30 patients with early-stage HCC,
and 57 samples were collected from patients with cirrhosis as
controls. Clinical samples were collected under a study protocol
set by ImCare Biotech and approved by each clinical site’s In-
stitutional Review Board.
HCC and control group criteria
HCC was diagnosed through biopsy or computed tomography/
MRI using Liver Imaging Reporting and Data System (LI-RADS)
classifications of LR4 and LR5 (28). The stage of HCC was de-
termined based on the BCLC staging system as set by American
Association for the Study of Liver Diseases guidelines (4). In the
control groups, healthy subjects had normal liver biochemistry
with no history of underlying liver and alcohol abuse. De-
termination of liver cirrhosis was based on histological criteria,
FibroScan (score.12 kPa), or clinical and radiological evidence
of portal hypertension. Follow-up imaging for cirrhotic patients
at least 6 months after the blood draw did not show that any had





developedHCC.Noncirrhotic hepatitis B subjects were defined as
being surface protein positive with detectable HBV DNA,
whereas noncirrhotic hepatitis C patients were defined as having
detectable anti-HCV antibody and HCV RNA.
Statistical analysis
Statistical analyses were conducted on all the data collected,
together with the relevant clinical information using IBM
software SPSS 24 (IBM, Armonk, NY). The serum level of
LC-SPIK and the resulting distribution were analyzed for the
HCC group and each of our control groups. Values of LC-
SPIK and 95% confidence intervals were calculated and vi-
sualized by boxplot. Comparisons of LC-SPIK levels in the
HCC group and each control group were performed using
nonparametric 1-way ANOVA (post-hoc multiple) com-
parisons (Tukey HSD), with P values,0.05 being considered
statistically significant. Similar analysis was performed for
patients by age, sex, ethnicity, BCLC stage, and LI-RADS
classification.
Receiver operating characteristic (ROC) curves were
constructed using HCC patients and controls with liver
disease (chronic HBV/HCV and cirrhosis, excluding healthy
patients). For LC-SPIK, an optimal cutoff value of 21.5 ng/
mL was determined by analyzing the ROC curve and
choosing a cutoff value that maximizes sensitivity and
specificity for the detection of HCC. This was then used to
calculate test sensitivity and specificity. ROC analysis of
AFP was also performed, and its sensitivity and specificity
were then compared with LC-SPIK.
Similar analysis was performed for the validation study,
and details are provided in the Supplementary Material
(Supplementary Digital Content 1, http://links.lww.com/
CTG/A434). The same cutoff value of LC-SPIK (21.5 ng/mL)
was confirmed as optimal in the validation study.
Figure 1. (a) Structural difference between LC-SPIK and pan-SPIK. (b) 96-well plates were immobilized using polyclonal anti-SPIK antibody “poly A” and
then incubated with either LC-SPIK from S2-3 cells or pan-SPIK from PanC1 cells (27). The binding activity was quantified by incubation with horse
peroxidase–labeled immobilized with a monoclonal anti-LC-SPIK antibody or poly A. (c) Western blot was used to confirm the difference between LC-SPIK
and pan-SPIK and the presence of LC-SPIK in HCC patient sera. HCC, hepatocellular carcinoma; LC-SPIK, liver cancer–secreted serine protease inhibitor
Kazal; pan-SPIK, pancreatic SPIK.
Figure 2. The cohorts of HCC patients and controls in primary and validation studies. The cohorts of HCC patients and controls in both the primary and
validation studies are shown. HCC patients in the primary study were further divided into different cohorts in this study according to BCLC stages, per
American Association for the Study of Liver Diseases recommendations. HCC, hepatocellular carcinoma.
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RESULTS
LC-SPIK is present in HCC patient’s sera but not pan-SPIK
Using our ELISA-based test, we demonstrated that the
monoclonal antibody IM-MCA only recognized LC-SPIK but
not pan-SPIK, whereas a polyclonal anti-SPIK antibody rec-
ognized both forms of SPIK (Figure 1b). Furthermore, we
confirmed that LC-SPIK was structurally different from pan-
SPIK because of the retention of an extra N-terminal frag-
ment (Figure 1a). Finally, using western blot, we showed that
LC-SPIK was the only form present in the sera of HCC pa-
tients (Figure 1c).
Patient characteristics
A total of 488 patients were enrolled in the primary study,
including 164 withHCC and 324withoutHCC. Patient cohorts
are detailed in Figure 2, whereas all patient demographics and
disease etiology are given in Table 1. Most study participants
(65.2%) were men, whereas 34.8% were women; 44.5% of
participants self-identified as White, 25.0% as Asian, 24.0% as
African American, and 6.4% as other minority, which includes
non-White Hispanic, Alaskan Native, and Native American.
Regarding disease etiology, for the liver cirrhosis cohort, 27%
of patients had HCV, 25% had HBV, and 21% had nonviral
Table 1. Patient cohorts and their distributions by age, sex, and race
Cohort Case
Disease association Age (yr) Sex Race
HBV HCV Nonviral ND <36 36–50 51–60 >60 Men Women White Black Asian cOther minority
HCCa 164 16 77 39 32 1 14 58 91 130 34 68 71 19 6
14.0% 62.2% 23.8% 20% 0.6% 8.5% 35.4% 55.5% 79.3% 20.7% 41.5% 43.3% 11.6% 3.7%
Cirrhosisb 125 31 34 26 34 3 24 48 50 76 49 70 25 23 7
24.8% 27.2% 20.8% 27.2% 2.4% 19.2% 38.4% 40.0% 60.8% 39.2% 56.0% 20.0% 18.4% 5.6%
HBV/HCV 120 81 39 NA 0 38 40 22 20 65 55 23 18 68 11
67.5% 32.5% 31.7% 33.3% 18.3% 16.7% 54.2% 45.8% 19.2% 15.0% 56.7% 9.2%
Healthy 79 NA NA NA NA 14 18 23 24 47 32 49 6 15 9
17.7% 22.8% 29.1% 30.4% 59.5% 40.5% 62.0% 7.6% 19.0% 11.4%
Total 488 62 103 155 192 334 178 228 123 128 33
12.1% 20.1% 30.3% 37.5% 65.2% 34.8% 44.5% 24.0% 25.0% 6.4%
HBC, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NA, not applicable; ND, not determined.
aNonviral HCC includes alcoholic and other kind of liver cancer.
bNonviral cirrhosis incudes NASH cirrhosis, autoimmune, alcoholic cirrhosis, etc.
cOther minority includes Hispanic, American Indian, or Alaska Native
Figure 3. Serum LC-SPIK levels in HCC patients and controls; 10 mL serum from HCC patients and controls were evaluated using an ELISA test kit. (a)
Distribution of serum LC-SPIK levels are compared and visualized for 164 HCC patients and each control group (125 cirrhosis, 120 hepatitis B/C, and 79
healthy subjects). (b) LC-SPIK levels in 81 patients with early-stage HCC are compared with control groups. (c) The mean, median, minimum, and
maximumLC-SPIK values for each patient group are listed. HCC, hepatocellular carcinoma; LC-SPIK, liver cancer–secreted serine protease inhibitor Kazal.





conditions. In the HCC group, more than 60% of the patients
were infected with HCV, whereas 14.0% hadHBV and 23.8% had
nonviral conditions (Table 1).
Of the 164HCCpatients, 81 were considered early-stageHCC
(6 BCLC stage 0 and 75 BCLC stage A), and 83 were considered
late-stage HCC (42 BCLC stage B, 35 BCLC Stage C, and 6 BCLC
stage D) (Figure 2). In this study, 110 HCC patients had a LI-
RADS score of 5, whereas 43 had a LI-RADS score of 4 (see Table,
Supplemental Digital Content 2, http://links.lww.com/CTG/
A434).
Of these 153 patients, 10 patients with LI-RADS (LR)-5 scores
and 5 patients with LR-4 scores were further confirmed by biopsy.
The remaining 11 patients who did not have LR-4/LR-5 scores were
confirmed using biopsy alone, for a total of 26 biopsy-confirmed
patients.
Serum LC-SPIK is significantly elevated in HCC patients,
including early-stage HCC
The mean serum level of LC-SPIK in all HCC patients was 45.2
ng/mL (95% confidence interval [CI]: 40.5–49.9), which was
significantly higher than that in all control groups (P, 0.001)
(Figure 3a,c). There was no statistically significant difference in
serum LC-SPIK levels among subgroups of HCC patients
based on age, sex, race, or LI-RADS classification (all P. 0.3)
(see Table, Supplemental Digital Content 2, http://links.lww.
com/CTG/A434). The existing pan-SPIK did not interfere in
the detection of LC-SPIK in blood (see Figure, Supplemental
Digital Content 3, http://links.lww.com/CTG/A434).
For the 81 patients with early-stage HCC (BCLC stage 0 and
A), the mean concentration of serum LC-SPIK was 38.1 ng/mL
(95% CI: 32.1–44.2) and was significantly different from the se-
rum LC-SPIK levels in all control groups (P , 0.001)
(Figure 3b,c). Late-stage HCC (BCLC stages B, C, and D) had a
significantly higher mean LC-SPIK level of 52.2 ng/mL (95% CI:
45.3–59.1) compared with early-stageHCC (38.1 ng/mL, 95%CI:
32.1–44.2) (P 5 0.009) (Table 2). No statistically significant dif-
ference was found in LC-SPIK levels characterized by individual
BCLC stages (all P . 0.250) (Table 3).
LC-SPIK performance in detecting HCC of any stage
The AUC for LC-SPIK in detecting HCC using patients with
liver disease as controls was 0.87 (95% CI: 0.83–0.91), com-
pared with 0.70 (95% CI: 0.64–0.76) for AFP. Using 21.5 ng/
mL as a cutoff value for serum LC-SPIK, the sensitivity and
specificity of LC-SPIK were 80% and 90%, respectively.
Comparatively, using 20.0 ng/mL as a cutoff value of serum
AFP, the sensitivity and specificity were only 52% and 86%,
respectively, which is significantly lower than that of LC-SPIK
(P , 0.05) (Figure 4a,c). When using cirrhotic patients alone
as the control, LC-SPIK had an AUC of 0.82 (95% CI:
0.77–0.87), with 80% sensitivity and 82% specificity, whereas
AFP had an AUC of 0.67 (95% CI: 0.61–0.74), with 52%
sensitivity and 78% specificity (Figure 4b,d).
LC-SPIK performance in detecting early-stage HCC
The area under the curve (AUC) for LC-SPIK in detecting
early-stage HCC using patients with liver disease as controls
was 0.85 (95% CI: 0.79–0.90), compared with only 0.61 (95%
CI: 0.52–0.69) for AFP. Using 21.5 ng/mL as cutoff value,
sensitivity of LC-SPIK in detecting HCC in its early stages was
72% with 90% specificity, which is significantly higher than
the 42% sensitivity and 86% specificity for AFP (Figure 4a,e).
When using cirrhotic patients alone as the control, LC-SPIK
had an AUC of 0.77 (95% CI: 0.71–0.84), with 72% sensitivity
and 82% specificity, whereas AFP had an AUC of 0.59 (95%
CI: 0.50–0.67), with 42% sensitivity and 78% specificity
(Figure 4b,f).
Table 2. Liver cancer–secreted serine protease inhibitor Kazal levels in patients, early- vs late-stage HCC
Cohort No. of cases Mean (ng/mL)
95% confidence interval for mean
P value for comparisons between each groupaLower bound Upper bound
Early-stage HCC 81 38.1 32.1 44.2 0.003
Late-stage HCC 83 52.2 45.3 59.1
HCC, hepatocellular carcinoma.
aDifferences are considered significant at P, 0.05.
Table 3. Liver cancer–secreted serine protease inhibitor Kazal levels in patients by Barcelona Clinic Liver Cancer stage
Cohort No. of cases Mean (ng/mL)
95% confidence interval for mean
P value for comparisons between each groupaLower bound Upper bound
Stage 0 6 33.7 17.1 50.2 0.250–0.998
Stage A 75 39.6 32.9 46.4
Stage B 42 48.9 39.3 58.5
Stage C 35 51.1 40.9 61.4
Stage D 6 65.6 22.7 108.6
aDifferences are considered significant at P, 0.05.
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LC-SPIK performance in HCC patients with false-negative
AFP results
Of 164 HCC patients, serum of 77 patients (47%) showed false-
negative AFP test results. LC-SPIK correctly detected HCC in 55
of these 77 patients (71%) (Figure 5a,c). For early-stage HCC,
AFP gave a false-negative result in 46 of 81 patients (57%). LC-
SPIK correctly detected early-stageHCC in 30 of these 46 patients
(65%) (Figure 5b,c).
Figure 4. ROC curves of LC-SPIK and AFP in distinguishing HCC with liver disease (cirrhosis and chronic hepatitis B/hepatitis C viruses) as control or
cirrhosis alone as control. The ROC curves of LC-SPIK and AFP in HCC/early-stage HCC patients were constructed using patients with liver disease as the
control or cirrhoticpatients aloneas the control and thencompared. (a) TheAUC, sensitivity, and specificity of LC-SPIKandAFP in distinguishingHCC/early-
stageHCC from liver disease are listed. (b) TheAUC, sensitivity, and specificity of LC-SPIKandAFP in distinguishingHCC/early-stageHCC fromcirrhosis are
listed. (c) ROC curve of LC-SPIK and AFP in distinguishing all HCC from liver disease. (d) ROC curve of LC-SPIK and AFP in distinguishing all HCC from
cirrhosis. (e) ROC curve of LC-SPIK and AFP in distinguishing early-stageHCC from liver disease. (f) ROC curve of LC-SPIK and AFP in distinguishing early-
stageHCC fromcirrhosis. ALP,a-fetoprotein;HCC, hepatocellular carcinoma; LC-SPIK, liver cancer–secreted serine protease inhibitor Kazal; ROC, receiver
operating curve.
Figure5.PositiveLC-SPIK results inHCCpatientswith false-negativeAFP results. (a) For all patientswithpositive LC-SPIK test results but false-negativeAFP
results, their measured serum LC-SPIK and AFP levels are plotted against each other. The position along the x axis indicates serum LC-SPIK level, whereas
position along the y axis represents serumAFP level. Each dot represents 1 patient. The cutoff value is 21.5 ng/mL for LC-SPIK and 20.0 ng/mL for AFP. (b)
Similar data for patients with early-stage HCC is shown. (c) The number of HCC patients, whose LC-SPIK is true positive but AFP is false negative. ALP,
a-fetoprotein; HCC, hepatocellular carcinoma; LC-SPIK, liver cancer–secreted serine protease inhibitor Kazal.






To validate the discriminative power of LC-SPIK, a blinded
validation study was performed using an independent cohort
of 45 HCC patients, which included 30 with early-stage HCC
and 57 cirrhotic controls (Figure 1). In this study, the mean
serum LC-SPIK level in HCC was 34.2 ng/mL (95% CI:
27.4–41.1), which was significantly higher compared with
cirrhotic controls at 19.3 ng/mL (95% CI: 16.9–21.6, P ,
0.001) (see Table, Supplemental Digital Content 4, http://
links.lww.com/CTG/A434). The optimal cutoff value of LC-
SPIK for HCC was evaluated and remained at 21.5 ng/mL, the
same as previously determined in our primary study pop-
ulation. The sensitivity of LC-SPIK was 80%, which is exactly
the same as in the primary study and was significantly higher
than AFP, which had only 51% sensitivity. The specificity of
LC-SPIK in the validation study was 72%, which is lower than
that in the primary study (82%) but still within the range of
noninferiority (see Table, Supplemental Digital Content 5,
http://links.lww.com/CTG/A434). Similar results were found
in patients with early-stage HCC, where LC-SPIK had 70%
sensitivity and was much higher than that of AFP (41%) (see
Table, Supplemental Digital Content 5, http://links.lww.com/
CTG/A434). The validation study did not show a statistically
significant difference for specificity between AFP and
LC-SPIK.
DISCUSSION
Early HCC detection with an accurate biomarker remains an
unmet need. Our study demonstrated that serum LC-SPIK can
reliably detect HCC and differentiate between HCC from other
liver disease states. Using a cutoff value of 21.5 ng/mL, LC-SPIK
was 80% sensitive and 90% specific in detecting HCC at any
stage and was 72% sensitive in detecting early stage. In addition,
LC-SPIK correctly detected HCC in 5 of 6 patients (83.3%) with
very early-stage HCC (BCLC stage 0). Compared with AFP, the
biomarker that is most frequently used for HCC detection, LC-
SPIK demonstrated higher sensitivity and specificity for all
stages ofHCC. In addition, LC-SPIK correctly identifiedHCC in
most cases where AFP provides a false-negative result, even for
early HCC. These results provide evidence that LC-SPIK is a
robust diagnostic biomarker that is superior to AFP, particularly
for early-stage HCC.
We also evaluated whether the level of LC-SPIK correlated
with the stage of cancer progression. First, we examined the
mean levels of LC-SPIK in sera from different stages of HCC,
as defined by the BCLC guidelines. This resulted in 5 different
stages (shown in Table 3). The mean values of LC-SPIK were
consistently higher for late and more advanced stages. Pa-
tients in the very early-stage group (BCLC stage 0) had the
lowest mean LC-SPIK value of only 33.7 ng/mL, whereas
terminal stage D patients had the highest mean LC-SPIK
value of 65.6 ng/mL. Analysis based strictly on BCLC clas-
sification, however, led to overstratification and uneven
sample sizes, especially for hard to recruit groups such as the
BCLC stage 0 (very early) and stage D (terminal) groups.
Thus, the results were not statistically significant (P . 0.05)
(Table 3).
We subsequently performed similar analysis focusing on
early- and late-stage HCC as defined previously. The mean level
of LC-SPIK for patients in the early-stage group was 38.1 ng/mL
(95% CI: 32.1–44.2), whereas the mean level of LC-SPIK in the
late-stage group was 52.2 ng/mL (95% CI: 45.3–59.1). Com-
paring these values, we do see a statistically significant difference
between the 2 groups (P , 0.05), showing that there is a cor-
relation between progression of HCC by stage and increased
levels of LC-SPIK. Although further study is required, these
results suggest that LC-SPIK might have potential as a tool to
monitor HCC progression.
In this study, we also observed that serum LC-SPIK tested
above the 21.5 ng/mL cutoff value in a total of 25 of 324 controls
(7.7%). Of these, there were 23 of 125 cirrhotic patients (18.4%)
and 2 of 37 HCV-infected patients (5.4%). No false-positive re-
sults for LC-SPIK were found in any of the 83 HBV-infected
patients or 79 healthy subjects (see Table, Supplemental Digital
Content 6 6, http://links.lww.com/CTG/A434). Cirrhotic pa-
tients had the highest rate of LC-SPIK positive test results, which
might be related to the fact that they also have the highest risk of
developing HCC.
The encouraging performance of LC-SPIK as a single bio-
marker makes it attractive to combine with other novel or
existing HCC diagnostic tests. Studies show that there is po-
tential for improvement when combining biomarkers into a
panel, such as with the GALAD score, which showed improved
sensitivity and specificity over AFP, AFP-L3, and des-g-(4)
prothrombin alone in some cases (29). The performance of
LC-SPIK might be further improved when combined with
other biomarkers, clinical information, and/or even imaging
technologies, such as MRI with hepatobiliary contrast agent
(gadoxetic acid), which has been shown to greatly improve
early stage HCC detection (30). The potential for improved
sensitivity and specificity could enhance the efficacy of sur-
veillance programs of high-risk patients and ability to detect
early-stage HCC.
In summary, we were able to generate strong evidence that
serum LC-SPIK might be applied as a novel diagnostic bio-
marker for detection of HCC, especially in its early and most
treatable stages. It showed much higher sensitivity and speci-
ficity than AFP and compared, especially, favorably for pa-
tients with early-stage HCC and those with non–AFP-
secreting HCC. Further prospective, longitudinal studies
with LC-SPIK, either alone or in combination with other HCC
diagnostic tests, might be needed to fully evaluate its clinical
utility as a tool for HCC surveillance in diverse patient pop-
ulations and clinical settings.
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Study Highlights
WHAT IS KNOWN
3 HCC is deadly, but survival significantly improves with early
detection.
3 There is an unmet need for effective HCC surveillance tools.
WHAT IS NEW HERE
3 Liver cancer–secreted serine protease inhibitor Kazal
(LC-SPIK) is a new biomarker for HCC.
3 LC-SPIK detects HCC with high sensitivity and specificity and
significantly outperforms AFP.
TRANSLATIONAL IMPACT
3 LC-SPIK can be used as an excellent biomarker for HCC
surveillance and discovering HCC in its early and treatable
stage.
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